Methodology approach to developing criteria for selecting hemophilia drugs included in the High-Cost Nosology program
https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.378
Abstract
Background. Hemophilia is a rare disease covered by Russia’s federal program for 14 High-Cost Nosologies (HCN), which ensures nationwide access to expensive drug therapies funded from the federal budget. The program currently includes 11 hemophilia drug products; however, the absence of transparent, clinically grounded criteria for selecting among these options in specific clinical scenarios complicates therapeutic decision-making.
Objective: To conduct a systematic review of the clinical effectiveness for hemophilia drugs included in the 14 HCN program and to develop an approach for establishing treatment selection criteria for specific patient groups.
Material amd methods. A literature search was performed in PubMed/MEDLINE and the Cochrane Library. Comparative clinical trials, systematic reviews, and meta-analyses were included. In addition, clinical guidelines for hemophilia and prescribing information for the relevant drugs were analyzed.
Results. The available evidence base is heterogeneous and does not permit a comprehensive comparison of all drugs included in the program. Nevertheless, several patterns in clinical effectiveness and important limitations of the evidence relevant to treatment selection were identified. Based on clinical trial data, clinical guidelines, and prescribing information, a methodological approach for developing drug selection criteria was proposed. This approach incorporates patient models, typical clinical scenarios, and an automated treatment selection algorithm.
Conclusion. The proposed approach may support the standardization of prescribing in hemophilia and can be adapted for other diseases included in the 14 HCN program.
About the Authors
A. G. Kharitonova
Center for Healthcare Quality Assessment and Control; Sechenov University
Russian Federation
Russian Federation
Anna G. Kharitonova
6/20 bldg 2 Pokrovsky Blvd, Moscow 109028;
8 bldg 2 Trubetskaya Str., Moscow 119048
V. V. Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Vitaly V. Omelyanovskiy, Dr. Sci. Med., Prof.
WoS ResearcherID: P-6911-2018, Scopus Author ID: 6507287753.
6/20 bldg 2 Pokrovsky Blvd, Moscow 109028;
2 bldg 1 Barrikadnaya Str., Moscow 123995
K. I. Matrenin
Center for Healthcare Quality Assessment and Control
Russian Federation
Russian Federation
Kirill I. Matrenin
6/20 bldg 2 Pokrovsky Blvd, Moscow 109028
A. A. Kingshott
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education; Financial Research Institute
Russian Federation
Russian Federation
Anastasiya A. Kingshott
6/20 bldg 2 Pokrovsky Blvd, Moscow 109028;
2 bldg 1 Barrikadnaya Str., Moscow 123995;
3 bldg 2 Nastasyinskiy Passage, Moscow 125375
References
1. Rubricator of clinical guidelines. Hemophilia. 2023. Available at: https://cr.minzdrav.gov.ru/view-cr/127_2 (in Russ.) (accessed 03.04.2026).
2. Deev I.A., Kobyakova O.S., Starodubov V.I., et al. Morbidity of the entire population of Russia in 2024: statistical materials. Мoscow: Central Research Institute for Organization and Informatization of Health Care; 2025: 244 pp. (in Russ.).
3. Ministry of Health of the Russian Federation. List of rare (orphan) diseases. Available at: https://minzdrav.gov.ru/en/documents/9863-perechen-redkih-orfannyh-zabolevaniy (in Russ.) (accessed 27.04.2026).
4. Zozulya N.I., Dimitrieva O.S. Unsolved issues of treatment of adult patients with hemophilia A. Therapeutic Archive. 2022; 94 (1): 77–82 (in Russ.). https://doi.org/10.26442/00403660.2022.01.201321.
5. The State Register of Medicines. Coagulation factor VIII. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=516c4693-2f41-4bbf-8bec-db9cd0e88729 (in Russ.) (accessed 28.08.2025).
6. The State Register of Medicines. Coagulation factor VIII + von Willebrand factor. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=ede00ca5-5c4f-4f2a-8c5d-d9649b7c3ab5 (in Russ.) (accessed 28.08.2025).
7. The State Register of Medicines. Anti-inhibitor coagulant complex. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=56556379-2fe0-409d-881a-0e4e0b867d60 (in Russ.) (accessed 25.05.2026).
8. The State Register of Medicines. Octocog alfa. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=ff2237a5-4286-4668-b747-213809e41bb7 (in Russ.) (accessed 28.08.2025).
9. The State Register of Medicines. Moroctocog alfa. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=a208a0f9-a111-499b-925d-2e6040fce987 (in Russ.) (accessed 30.08.2025).
10. The State Register of Medicines. Eptacog alfa (activated). Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=8174b697-0ed7-4bd8-8081-a6c61ef56351 (in Russ.) (accessed 31.08.2025).
11. The State Register of Medicines. Simoctocog alfa. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=7c6d9670-4c4a-449b-973d-fd3dd974a329 (in Russ.) (accessed 28.08.2025).
12. The State Register of Medicines. Efmoroctocog alfa. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e86d9a30-5c72-4332-841b-6f260e3dfb4b (in Russ.) (accessed 04.09.2025).
13. The State Register of Medicines. Emicizumab. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=d7c799f0-3de5-4279-9203-90fc46470e9e (in Russ.) (accessed 25.05.2026).
14. The State Register of Medicines. Coagulation factor IX. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=15c1332a-975f-4bdb-a29b-55c378c70ad1 (in Russ.) (accessed 30.08.2025).
15. The State Register of Medicines. Nonacog alfa. Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=4caf72ff-8a29-4d8a-b6c8-950081ecec08 (in Russ.) (accessed 30.08.2025).
16. Оmelyanovskiy V.V., Kutsev S.I., Mukhortova P.A., et al. Approaches to reduce the uncertainty in the clinical efficacy of orphan drugs. Kachestvennaya Klinicheskaya Praktika / Good Clinical Practice. 2024; 4: 82–96 (in Russ.). https://doi.org/10.37489/2588-0519-2024-4-82-96.
17. Mahlangu J., Powell J.S., Ragni M.V., et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123 (3): 317–25. https://doi.org/10.1182/blood-2013-10-529974.
18. Antunes S.V., Tangada S., Stasyshyn O., et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014; 20 (1): 65–72. https://doi.org/10.1111/hae.12246.
19. Peyvandi F., Castaman G., Gresele P., et al. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019; 17 (5): 391–8. https://doi.org/10.2450/2019.0183-18.
20. Lissitchkov T., Klukowska A., Pasi J., et al. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Ther Adv Hematol. 2019; 10: 2040620719858471. https://doi.org/10.1177/2040620719858471.
21. Valentino L.A., Rusen L., Elezovic I., et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 2014; 20 (3): 398–406. https://doi.org/10.1111/hae.12344.
22. Santoro C., Fuh B., Le P.Q., et al. Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81-8973): final results of the global real-world study, TAURUS. Eur J Haematol. 2023; 110 (1): 77–87. https://doi.org/10.1111/ejh.13876.
23. Nolan B., Mahlangu J., Pabinger I., et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study. Haemophilia. 2020; 26 (3): 494–502. https://doi.org/10.1111/hae.13953.
24. Rusen L., Kavakli K., Korth-Bradley J., et al. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: two open-label studies. Haemophilia. 2018; 24 (4): 604–10. https://doi.org/10.1111/hae.13466.
25. Mahlangu J., Oldenburg J., Paz-Priel I., et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. New Engl J Med. 2018; 379 (9): 811–22. https://doi.org/10.1056/NEJMoa1803550.
26. Oldenburg J., Mahlangu J.N., Kim B., et al. Emicizumab prophylaxis in hemophilia A with inhibitors. New Engl J Med. 2017; 377 (9): 809–18. https://doi.org/10.1056/NEJMoa1703068.
27. van der Zwet K., de Kovel M., Motwani J., et al. Bleeding control improves after switching to emicizumab: real-world experience of 177 children in the PedNet registry. Haemophilia. 2024; 30 (3): 685–92. https://doi.org/10.1111/hae.15015.
28. McCary I., Guelcher C., Kuhn J., et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020; 26 (4): 631–6. https://doi.org/10.1111/hae.14005.
29. Ljung R., Chan A.K.C., Glosli H., et al. BAY 81-8973 efficacy and safety in previously untreated and minimally treated children with severe hemophilia A: the LEOPOLD Kids Trial. Thromb Haemost. 2023; 123 (1): 27–39. https://doi.org/10.1055/s-0042-1757876.
30. Young G., Liesner R., Chang T., et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019; 134 (24): 2127–38. https://doi.org/10.1182/blood.2019001869.
31. Reyes A., Révil C., Niggli M., et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019; 35 (12): 2079–87. https://doi.org/10.1080/03007995.2019.1649378.
32. Oldenburg J., Hay C., Peyvandi F., et al. A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A. Hematology. 2025; 30 (1): 2513186. https://doi.org/10.1080/16078454.2025.2513186.
33. Astermark J., Donfield S.M., DiMichele D.M., et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007; 109 (2): 546–51. https://doi.org/10.1182/blood-2006-04-017988.
34. Andreeva T.A., Zorenko V.Y., Davydkin I.L., et al. Efficiency and safety of Innonafactor in prevention of bleeding episodes in patients with severe and moderate hemophilia B: results of part 1 of phase II–III clinical trial. Pediatric Hematology/Oncology and Immunopathology. 2015; 14 (1): 65–75 (in Russ). https://doi.org/10.24287/1726-1708-2015-14-2-50-58.
35. Auerswald G., Thompson A.A., Recht M., et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012; 107 (6): 1072–82. https://doi.org/10.1160/TH11-09-0642.
36. Feng X., Zhou X., Sun J., Wang Z. Efficacy and safety of recombinant factor VIII in previously untreated and previously treated children with hemophilia A: a systematic review. Adv Ther. 2025; 42 (5): 2019–39. https://doi.org/10.1007/s12325-025-03110-0.
37. Klukowska A., Szczepański T., Vdovin V., et al. Long-term tolerability, immunogenicity and efficacy of Nuwiq® (human-cl rhFVIII) in children with severe haemophilia A. Haemophilia. 2018; 24 (4): 595–603. https://doi.org/10.1111/hae.13460.
38. Shima M., Nogami K., Nagami S., et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019; 25 (6): 979–87. https://doi.org/10.1111/hae.13848.
39. Muniz R.L., Camelo R.M., Araújo M.S., et al. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis. Expert Rev Hematol. 2023; 16 (12): 1087–97. https://doi.org/10.1080/17474086.2023.2293096.
40. Prudente T.P., Camelo R.M., Guimarães R.A., Roberti M.D.R.F. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis. Sao Paulo Med J. 2024; 142 (5): e2023102. https://doi.org/10.1590/1516-3180.2023.0102.R1.20022024.
41. Iorio A., Matino D., D’Amico R., Makris M. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2010; 8: CD004449. https://doi.org/10.1002/14651858.CD004449.pub3.
42. Matino D., Makris M., Dwan K., et al. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015; 2015 (12): CD004449. https://doi.org/10.1002/14651858.CD004449.pub4.
43. Bell S.A., Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9(1):170. doi: https://doi.org/10.1186/s13023-014-0170-0.
44. Logviss K., Krievins D., Purvina S. Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study. PLoS ONE / ed. Rosenkranz G. 2018;13(4):e0194494. doi: https://doi.org/10.1371/journal.pone.0194494.
45. Page A.T., Potter K., Clifford R., McLachlan A.J., Etherton-Beer C. Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. Internal medicine journal. 2016; 46(10): 1189-1197. https://doi.org/10.1111/imj.13215
46. Finlay A.Y. Current severe psoriasis and the rule of tens. British Journal of Dermatology. 200;152(5): 861-7. https://doi.org/10.1111/j.1365-2133.2005.06502.x
Review
For citations:
Kharitonova A.G., Omelyanovskiy V.V., Matrenin K.I., Kingshott A.A. Methodology approach to developing criteria for selecting hemophilia drugs included in the High-Cost Nosology program. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.378
Views:
54
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 